导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.23% | 2875/4773 |
| 近一周 | -2.19% | 1449/5462 |
| 近一月 | -4.19% | 2287/5421 |
| 近一季 | -7.59% | 2460/5209 |
| 近半年 | -3.07% | 2115/4920 |
| 近一年 | 0.25% | 2608/4366 |
| 近两年 | 44.52% | 1663/2954 |
| 近三年 | 26.53% | 1204/2253 |
| 成立以来 | 24.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.66% 3339/4961 |
12.01% 2253/5312 |
- - |
- - |
| 2025 | 19.51% 2210/4813 |
-0.99% 2519/3635 |
2.15% 1817/4076 |
17.92% 2395/4524 |
0.21% 2130/4813 |
| 2024 | 16.46% 807/3463 |
2.79% 702/2808 |
-1.28% 1018/3014 |
16.73% 1367/3129 |
-1.67% 1788/3463 |
| 2023 | -9.26% 1141/2656 |
4.18% 1026/2280 |
-3.93% 970/2385 |
-2.98% 814/2515 |
-6.56% 1825/2655 |
| 2022 | -19.44% 851/2207 |
-13.99% 885/1919 |
6.74% 615/2016 |
-13.72% 958/2113 |
1.69% 1177/2208 |
| 2021 | -3.56% 914/1822 |
-3.07% 753/1255 |
4.09% 924/1330 |
-5.73% 849/1466 |
1.39% 948/1822 |
| 2020 | 27.27% 586/1250 |
-9.71% 712/1028 |
13.29% 630/1067 |
10.39% 559/1164 |
12.71% 439/1184 |
| 2019 | 35.46% 376/1092 |
26.39% 409/754 |
-0.39% 259/804 |
0.63% 496/850 |
6.92% 516/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.85% 367/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏沪深300ETF联接C VS. 长安沪深300非周期A(740101) |